USPTO Form 1449. The C.S. Department of Commerce Patent and Trademark Office				Attorney Docket No.		Serial No.			
INFORMATION DISCLOSURE STATEMENT				11111/2003C			10/666,834		
n vi Oldvi	1110111	7.0000001000100		Applicant(s):. Segal, et al.					
•				Filing Date: September 19, 2003			Group: Not Yet Assigned		
U.S. PATENT DOCUMENTS									
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)		
FOREIGN PATENT DOCUMENTS									
Examiner		Document No.	Publication	Country	Class	Subclass	Translation		
Initial			Date				YES	NO	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)									
ea	1.	Faulkner, L. et al., (2001), "IL-2 linked to a peptide from influenza hemagglutinin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells", <i>International Immunology</i> , 13(6):713-721							
	2.	Batova, A. et al., (1999), "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro", Clinical Cancer Research, 5:4259-4263.							
	3.	Frankel, A. et al., (1995), "IL2-Ricin Fusion Toxin Is Selectively Cytotoxic in Vitro to IL2 Receptor-Bearing Tumor Cells", Bioconjugate Chem., 6:666-672.							
	4.	Gillies, S.D. et al., (1992), "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells", <i>Proc. Natl. Acad. Sci. USA</i> , 89:1428-1432.							
	5.	Barker, E. et al., (1991), "Effect of a Chimeric Anti-Ganglioside G _{D2} Antibody on Cell-mediated Lysis of Human Neuroblastoma Cells", Cancer Research, 51:144-149.							
	6.	Gillies, S.D. et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody" <i>Hybridoma</i> , 10(3):347-356.							
U	7.	Deliyannis, G. et al., (2000), "A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge", <i>PNAS</i> , 97(12):6676-6680.							
EXAMIN	JER	Chil. Le			DATE C	CONSIDERED 9/2 9/05			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with									

**Copies of references not provided at the time of this submission.